Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men

European Journal of Preventive Cardiology

Volumn 21, Issue 8, 2014, Pages 972-979

  Nolte, Julia Eh ^a,b   Neumann, Till ^b   Manne, Jennifer M ^c   Lo, Janet ^a   Neumann, Anja ^b   Mostardt, Sarah ^b   Abbara, Suhny ^a   Hoffmann, Udo ^a   Brady, Thomas J ^a   Wasem, Juergen ^b   Grinspoon, Steven K ^a   Gazelle, G Scott ^a,c   Goehler, Alexander ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Coronary heart disease; cost effectiveness; HIV; Markov model; prevention

Indexed keywords

CARDIOVASCULAR AGENT;

ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; EXERCISE ELECTROCARDIOGRAPHY; EXERCISE TEST; FRAMINGHAM RISK SCORE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL LITERATURE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; STRESS ECHOCARDIOGRAPHY; ADULT; COMPLICATION; CORONARY ANGIOGRAPHY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; ELECTROCARDIOGRAPHY; INCIDENCE; MARKOV CHAIN; MASS SCREENING; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; X-RAY COMPUTED TOMOGRAPHY;

ADULT; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, STRESS; ELECTROCARDIOGRAPHY; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904888149     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313483607     Document Type: Article

References (30)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 ; 372: 293-299
2. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003 ; 33: 506-512 (Pubitemid 36886080)
3. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006 ; 7: 218-230
4. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007 ; 92: 2506-2512 (Pubitemid 47037350)
5. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010 ; 24: 243-253
6. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008 ; 118: e29 - e35
7. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010 ; 55: 615-619
8. Hsue PY, Squires K, Bolger AF, et al. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation. 2008 ; 118: e41 - e47
9. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97: 1837-1847 (Pubitemid 28213628)
10. Neumann T, Esser S, Potthoff A, et al. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007 ; 12: 243-248 (Pubitemid 47248964)
11. Deutsche AIDS-Gesellschaft e.V., Österreichische AIDS Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-1 Infektion. Deutsche AIDS-Gesellschaft e.V., Österreichische AIDS. Available at: http://www.rki.de/DE/Content/InfAZ/H/HIVAIDS/Therapie/Leitlinien/D-A- antiretroviral-03-10.pdf?-blob=publicationFile (2010, consulted December 2012).
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda: Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (2011, consulted December 2012).
13. Czoski-Murray C, Karnon J, Jones R, et al. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess. 2010 ; 14 ( 53 ):
14. Min JK, Lin FY, Dunning AM, et al. Incremental prognostic significance of left ventricular dysfunction to coronary artery disease detection by 64-detector row coronary computed tomographic angiography for the prediction of all-cause mortality: results from a two-centre study of 5330 patients. Eur Heart J. 2010 ; 31: 1212-1219
15. Ladapo JA, Jaffer FA, Hoffmann U, et al. Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol. 2009 ; 54: 2409-2422
16. Ostrom MP, Gopal A, Ahmadi N, et al. Mortality incidence and the severity of coronary atherosclerosis assessed by computed tomography angiography. J Am Coll Cardiol. 2008 ; 52: 1335-1343
17. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999 ; 159: 1197-1204 (Pubitemid 29269859)
18. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 ; 355: 251-259 (Pubitemid 44079340)
19. Greiner W, Claes C, Busschbach JJ, et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005 ; 6: 124-130 (Pubitemid 40905009)
20. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 ; 39: 69-77 (Pubitemid 40617021)
21. Yazdanpanah Y, Vray M, Meynard J, et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 ; 8: 439-450 (Pubitemid 47336785)
22. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999 ; 281: 1822-1829 (Pubitemid 29231133)
23. Hayashino Y, Nagata-Kobayashi S, Morimoto T, et al. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors. J Gen Intern Med. 2004 ; 19: 1181-1191 (Pubitemid 40041382)
24. Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006 ; 98: 774-782 (Pubitemid 43983301)
25. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003 ; 290: 86-97 (Pubitemid 37432870)
26. Quist-Paulsen P, Lydersen S, Bakke PS, et al. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 274-280 (Pubitemid 44097735)
27. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med. 2011 ; 12: 412-421
28. Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012 ; 19: 267-274
29. Wilson K, Hettle R, Marbaix S, et al. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. Eur J Prev Cardiol. 2012 ; 19: 1173-1183
30. Wallis M, Neilson F, Hogarth H, et al. Cumulative attendance, assessment and cancer detection rate over four screening rounds in five English breast-screening programmes: a retrospective study. J Public Health (Oxf). 2007 ; 29: 275-280